June 25, 2025

enGene Snags FDA RMAT Designation for Bladder Cancer Gene Therapy Detalimogene – CGTLive®

June 25, 2025

FDA Grants RMAT Designation for enGene’s Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer – BioSpace

June 25, 2025

FDA grants RMAT designation to enGene’s bladder cancer therapy By Investing.com – Investing.com Nigeria

June 25, 2025

Maximizing the impact: Nutrition and exercise for metastatic bladder cancer – Mayo Clinic Press

June 24, 2025

MRI Radiomics Predicts Bladder Cancer Response to Pembrolizumab in PURE-01 Study – Andrea Necchi – UroToday